Top Markets
Coin of the day
Medesis Pharma S.A. Medesis Pharma S.A.

Medesis Pharma S.A.

ALMDP
Rank in Stocks #37493
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development... Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Share Price
$0.38207938
Last synced: 2025-04-07
Market Cap
$1.67M
Change (1 day)
-0.39%
Change (1 year)
0.00%
Country
FR
Trade Medesis Pharma S.A. (ALMDP)

Category

EPS for Medesis Pharma S.A. (ALMDP)
EPS as of 2026 TTM: 0
According to Medesis Pharma S.A. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Medesis Pharma S.A. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE